Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Intuitive Surgical, Inc.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Strong business, valuation above the sector
3 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Stable quality
Profitability
4/4
Debt & liquidity
1/3
Efficiency
1/2
Ranked highest against the sector: fcf growth yoy: 1619% above the median (-7.73%). Intuitive Surgical, Inc. operates in the Health Care sector; its F-Score for the latest cycle is 6/9 (Stable quality). The archetype for the latest cycle reads Strong business, higher valuation, and the composite of 61/100 frames where the company sits against its sector. Among the key figures, the P/E is 49.4× against a sector median of 27.6×, revenue moved 20.5% year over year, operating margin was 29.3%, and ROE was 16.7% against a median of 26.6%. Free cash flow for the latest fiscal year came to $2.5B, net debt to $0, and market cap to $144.5B. The figures rest on 10-K/10-Q filings from SEC EDGAR; the full read, with all twelve percentile metrics, is on the methodology page.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie | 8/9 | 15 367% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth; analyst sentiment is steady; has mostly beaten consensus.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
The three-month change in the share of positive analyst ratings. This is sentiment, not an earnings-estimate revision, and not a call to act.
When ISRG reports on July 16, track revenue year over year alongside FCF conversion. The FCF growth rate is well above the sector median, but the FCF yield sits 51% below it — so watch whether higher earnings translate into yield improvement or remain compressed by the valuation.
Pull the most recent 10-K on SEC EDGAR and focus on the Management Discussion section covering operating leverage and capital allocation. With EV/EBITDA running 94% above the sector median of 21.0×, understanding what management says about sustaining that premium is worth the time.
From the same-sector table in section 06, pick two or three companies yourself and line up EV/EBITDA alongside FCF yield. ISRG carries a higher valuation multiple relative to the sector median, so placing it beside peers you select will give you a clearer sense of where that gap sits in context.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: -45%-22%+74%+91%
Over 4 years: 0.000.000.000.00
Over 4 years: +9%+14%+17%+21%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 8 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| +9% |
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health | 7/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical, Inc. | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →
The last few quarters are recent context, not a fixed rate. Consensus for near quarters is set low, so companies clear it routinely; over long horizons the forecasts run the other way, too high.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.